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Abstract
Osseointegration of dental implants can be promoted by implant-surface modifications using bisphosphonate 
coatings. In addition, it is of clinical interest to promote peri-implant bone formation and to restore bony 
structure in low bone-mass patients. The present study evaluated a combination of an anti-resorptive 
zoledronic acid (ZOL) implant-coating and a systemically applied sclerostin antibody, a known bone anabolic 
treatment principle, versus sole sclerostin antibody treatment or ZOL implant-coating in a rat osteoporosis 
model.
 Uncoated reference surface implants or ZOL-coated implants (n = 64/group) were inserted into the proximal 
tibia of aged osteoporotic rats three months following ovariectomy. 32 animals of each group received once 
weekly sclerostin antibody therapy. Osseointegration was assessed 2 or 4 weeks post-implantation by ex vivo 
µCT, histology and biomechanical testing.
 Overall implant survival rate was 97 %. Histomorphology revealed pronounced bone formation along 
the entire implant length of ZOL-coated implants. At 4 weeks following implant insertion, bone-implant 
contact, cancellous bone mineral density and bone volume/tissue volume were significantly increased for 
the combination of ZOL and sclerostin antibody as compared to sclerostin antibody or ZOL implant-coating 
alone. Removal torque was also significantly increased in the combination therapy group relative to animals 
receiving only sclerostin antibody therapy or ZOL-coated implants.
 In an osteoporotic rat model, the combination of anti-resorptive ZOL implant-coating and systemically 
applied sclerostin antibody led to significantly increased peri-implant bone formation. Therefore, the 
combination of ZOL and the osteoanabolic sclerostin antibody was more effective than either agent alone.
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Introduction
Long-term survival of dental implants depends on the 
mechanically stable fixation of an implant in the host 
bone (Branemark et al., 1977). Conditions affecting 
bone quality and quantity, such as osteoporosis, may 
limit an implant’s clinical success (Ihde et al., 2009; 
Scully et al., 2007). Postmenopausal osteoporosis is 
the most common type of osteoporosis. In Germany, 
it has a prevalence of about 59 % in women over 
75 years and leads to reduced bone mass and 
increased bone fragility (Haussler et al., 2007). In 
the USA, osteoporosis prevalence is 52 % in women 
over 80 years (Looker, 1995). Therefore, it could be 
hypothesised that dental implant loss would occur 
frequently in such patients with reduced bony 
template. Yet, apart from a positive correlation 
between systemic and alveolar bone loss (Jeffcoat, 
2006), no increased malfunction of dental implants 
has been reported to date (Holahan et al., 2008; Marco 
et al., 2005).
 Drugs for the treatment of osteoporosis are aimed 
at inhibiting ongoing catabolic bone resorption 
and/or promoting anabolic bone formation. It 
is currently unclear whether such drugs would 
also positively influence implant osseointegration 
and biomechanical competence. Clinically, 
bisphosphonates are commonly applied for the 
inhibition of osteoclastic bone resorption and bone 
loss in osteoporosis (Crandall et al., 2014). Zoledronic 
acid (ZOL) is an intravenously applied potent 
bisphosphonate commonly prescribed to patients 
suffering from postmenopausal osteoporosis. ZOL 
has a high affinity to mineralised bone tissue, where 
it inhibits the activity of bone-resorbing osteoclasts 
through suppression of farnesyl diphosphate 
synthase enzymatic activity (Lin, 1996). This leads 
to irreversible inhibition of osteoclast function and 
reduced osteoclast number.
 Both types of bone cells, osteoblasts and 
osteoclasts, also play a major role in peri-implant 
bone healing. Osseointegration of dental implants can 
be altered by several surface modifications, such as 
roughening or application of implant coatings with 
components of the extracellular matrix (Stadlinger 
et al., 2008; 2009), or with pharmaceutical agents. 
Bisphosphonates have been used as implant coatings 
in preclinical (Andersson et al., 2010; Gao et al., 2009; 
Stadlinger et al., 2013; Wermelin et al., 2007; Wermelin 
and Aspenberg et al., 2008) as well as clinical studies 
(Abtahi et al., 2010). Ovariectomised (OVX) rats are 
oestrogen-deprived and serve as an established 
model of postmenopausal osteoporosis. In this animal 
model, bisphosphonate-coated implants show a 
significantly higher bone-implant contact (BIC) and 
bone-volume density (BVD) as compared to reference 
surface implants (Stadlinger et al., 2013). In addition, 
other osteoporosis drugs, such as oestrogen (Duarte et 
al., 2005; Qi et al., 2004), strontium ranelate (Maimoun 
et al., 2010) or parathyroid hormone (Shirota et al., 
2003), are under preclinical investigation regarding 
their potential to promote osseointegration. Another 
promising emerging approach to osteoporosis 
therapy is the application of monoclonal sclerostin-
blocking antibodies. Sclerostin is a small secreted 
glycoprotein and a potent inhibitor of the bone 
anabolic canonical WNT/β-catenin signalling 
pathway (Baron and Kneissel, 2013; Delgado-Calle et 
al., 2017). It is predominantly expressed by osteocytes, 
terminally differentiated cells of the osteoblastic 
lineage. It binds to the canonical WNT co-receptors 
lipoprotein receptor-related protein-4 (LRP4), LRP5 
and LRP6, thereby, inhibiting bone formation of 
osteoblasts (Leupin et al., 2011; Poole et al., 2005). 
Additionally, osteoclast activity is increased as a 
result of sclerostin-mediated inhibition of WNT 
signalling (Delgado-Calle et al., 2017). Sclerostin 
loss-of-function in humans and animals leads to a 
large bone mass phenotype associated with normal 
bone quality. Sclerostin antibodies block the binding 
of sclerostin to LRP5/6 WNT signalling co-receptors, 
thereby resulting in elevated osteoblastic WNT 
signalling activity, which leads to increased bone 
formation and reduced bone resorption. Numerous 
animal studies have demonstrated the osteoanabolic 
effect of sclerostin antibodies. For example, in OVX 
rats, weekly application of sclerostin antibody 
leads to a significant improvement in bone mass 
and architecture after 12 months of observation 
(Ominsky et al., 2017). Similarly, it is of clinical 
interest whether sclerostin antibodies also promote 
osseointegration of dental implants, enabling a 
functional and aesthetic rehabilitation after tooth loss. 
Tooth extractions, e.g. due to caries or periodontitis, 
increase with age. Furthermore, many patients suffer 
from systemic diseases such as e.g. osteoporosis. 
Thus, the combination of systemic bone anabolic 
sclerostin antibody treatment for bone restoration 
with an implant surface coating for the improvement 
of peri-implant bone healing under compromised 
bone conditions may hold the potential to increase 
the number of patients that can benefit from dental 
implants.
 The present study evaluated the effect of systemic 
sclerostin antibody application and ZOL implant 
coating on peri-implant bone formation in a rat 
osteoporosis model. The hypothesis was that the 
combination of sclerostin antibody application and 
ZOL implant-coating increased the peri-implant bone 




The study experimental protocol and the animal 
care conformed to the Swiss federal law for animal 
protection under the control of the Basel-Stadt 
Cantonal Veterinary Office, Switzerland. 128 
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6-month-old female virgin Wistar rats underwent 
bilateral ovariectomy under general anaesthesia. 
14 weeks after surgery, the animals were randomised 
into two groups (64 rats/group) based on an even 
distribution of proximal tibial bone mineral density 
(BMD), as assessed by micro-computed tomography 
(µCT), and body weight as first and second rank 
parameters, respectively. Then, each animal received 
one implant in the left proximal tibia metaphysis. 
After implant insertion, 32 rats of each group received 
100 mg/kg sclerostin antibody applied intravenously 
once weekly until sacrifice. Animals were further 
randomised into two sub-groups (16 rats/sub-group) 
and sacrificed either 2 or 4 weeks following implant 
insertion, respectively (Fig. 1). Tibial bone samples 
from 8 animals per sub-group were assessed by µCT 
and histomorphometry. The additional 8 samples 
were utilised for biomechanical testing.
Implants
Experimental-threaded titanium implants (grade 
4), with major diameter 1.7 mm, minor diameter 
1.1 mm and length 3.0 mm, were used (Thommen 
Medical AG, Waldenburg, Switzerland). The head 
of the screw was of cylindrical shape to allow for 
coaxial alignment and equipped with an inverse slot 
drive. The surface of all implants was sandblasted 
and thermally acid-etched. The Sa value following 
this procedure is approximately 2.0 µm (Stadlinger 
et al., 2012a). These implants with reference surface 
(n = 64) were inserted in one experimental group. 
An additional 64 implants were coated with a ZOL-
stearate complex using 8.5 µg of ZOL acid per implant 
in a spray-coating process, as previously described 
(Stadlinger et al., 2013). All implants were sterilised 
by gamma-radiation before insertion.
Implant surgery
Animals were anaesthetised with 60 mg/kg ketamine 
and 8 mg/kg xylazine by intraperitoneal injection and 
received 0.05 mg/kg buprenorphine subcutaneously 
prior to implantation and 0.03 mg/kg twice daily 
for 2 d post-implantation for analgesic purposes. 
All operative procedures were performed under 
sterile conditions. For implant placement, a 15 mm 
longitudinal incision was made along the medial 
side of the left tibia and the musculo-periosteal flap 
was lifted, as described previously (Stadlinger et al., 
2013). A conical drill with a diameter of 1.1-1.5 mm 
was used under water-cooling for osteotomy 2 mm 
distal to the growth plate of the proximal tibia 
metaphysis. Implants were placed using an implant 
screwdriver. After placement, a rounded polyether-
ether-ketone healing cap was placed on the cuboid 
implant top. The soft tissue was repositioned and 
sutured in two layers, using resorbable sutures 
(Safil® 6×0, Braun, Melsungen, Germany). An 
aerosol bandage was applied (Flint MED, Togal-
Werk, München, Germany) and wound healing was 
controlled daily for the first week post-implantation 
and twice per week during the following healing 
period. All animals received fluorochrome markers 
Fig. 1. Study design. After sacrifice, 8 samples per group were analysed by µCT and histology and the 
other 8 samples were used for biomechanical testing. 
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by subcutaneous injection 10 d (alizarin complexone, 
20 mg/kg, Merck) and 3 d (calcein, 30 mg/kg, Sigma-
Aldrich) prior to sacrifice.
 124 of 128 rats completed the study, which 
represented an overall implant survival rate of 97 %. 
4 animals died during surgery or post-operative 
healing. Rats exhibited normal behaviour and no 
signs of abnormal wound healing or other overt 
phenotypes were observed.
Tissue processing
After sacrifice, the left tibiae were removed and the 
proximal halves were fixed in Schaffer’s solution for 
24 h at 4 °C, followed by storage in 70 % ethanol. 
Following ex vivo µCT analysis, the samples were 
dehydrated and embedded in methylmethacrylate 
to generate 50 µm-thick ground sections. These 
were cut in parallel to the implant length axis 
and perpendicular to the tibial axis, as described 
previously (Donath and Breuner, 1982). Fluorescent 
microscopy was performed prior to Masson-Goldner 
trichrome staining.
Computed tomography
For even distribution of the animals into groups, 
cross-sectional BMD was evaluated in the left 
proximal tibia metaphysis by peripheral quantitative 
computed tomography (pQCT, Norland XCT-2000; 
Stratec, Pforzheim, Germany) prior to implant 
surgery (fitted with an Oxford 50 AM X-ray tube 
and a 1 mm diameter collimator; voxel size: 
0.2 mm × 0.2 mm × 1 mm; scan speed: scout view 
20 mm/s; final scan: 10 mm/s, 1 block, contour mode 
1, peel mode 2; threshold: 610 mg/cm3).
 Ex vivo, µCT measurements were performed 
with a µCT 40 instrument [Scanco Medical; voxel 
size: 10 µm; 192 slices; energy: 70 kV, 114 µA; 
high resolution; integration time: 300 ms; cone 
beam continuous rotation] as previously described 
(Rebaudi et al., 2004). Bone and titanium were 
distinguished using the appropriate Gaussian filters 
(sigma 1.2, bone; 2.0, titanium; support 2, bone 3, 
titanium) and threshold procedures (bone: 370-700; 
titanium implant: 701-1000). BMD and bone volume/
tissue volume (BV/TV) were determined in the 
cancellous bone region surrounding the implant (3 
to 10 voxels distance from the implant) and in the 
region adjacent to it (10 to 23 voxels distance from the 
implant). Since results did not differ between the two 
regions, data were merged for the results presented 
in Fig. 5 and reflected a total width of 200 µm. In 
addition, BIC was determined.
Histomorphometry
Fluorescence microscopy was performed at up to 40× 
magnification (Olympus BX 61). Polyfluorochrome 
labels were qualitatively analysed for bone growth 
dynamics, location and label sequences. Subsequently, 
Masson-Goldner-trichrome-stained sections were 
imaged following alignment using a motorised 
measuring stage (Märzhäuser, Wetzlar, Germany) 
for multiple alignment scanning connected to a 
computerised system for histomorphometry (CellˆF, 
Imaging Software for Life Science, Olympus). BIC was 
measured in the cancellous bone compartment along 
the implant surface. The apex of the implant was not 
included. Cancellous bone area per tissue area (BA/
TA) was measured in a region adjacent to the implant 
and in the surrounding area, as described previously 
(Stadlinger et al., 2013).
Biomechanical evaluation
64 specimens (8 implants per group and healing 
time) underwent biomechanical testing at the day 
of harvest. Healing caps were removed and the 
tibiae were embedded in dental plaster (Fujirock EP, 
Improved type 4 dental stone, GC, Leuven, Belgium) 
using a custom potting device, which provided 
coaxial alignment of implant and actor of the testing 
machine. Specimens were mounted on a servo-
hydraulic testing machine (MTS 858 Mini Bionix, 
MTS Systems Corporation, Minneapolis, MN, USA) 
equipped with a 2 Nm load cell and signal amplifier 
(accuracy 2 Nmm; D2209; Lorenz Messtechnik, 
Alfdorf, Germany). A bellow clutch was used to 
compensate axial motion and a claw coupling to 
ensure neutral initial fixation (no moment). Implants 
were rotated counter-clockwise at the constant rate of 
0.5°/s until peak moment was passed and the residual 
friction moment was clearly reached. Moment 
and angle data were recorded for subsequent data 
analysis at a sampling rate of 50 Hz. Removal torque 
(RT: Nmm) was defined as the maximal torque and 
interfacial stiffness (Nmm/°) was calculated by linear 
interpolation of the moment-angle curve between 
20 % to 80 % of RT (MATLAB R2008, The MathWorks, 
Natick, MA, USA).
Statistical analysis
Data are presented as mean values ± standard 
deviation. Data distribution was tested by 
Kolmogorov-Smirnov test. Variance analysis of 
all groups by ANOVA with Bonferroni-adjusted 
multiple comparisons of mean values was performed. 
The level of significance was set to p = 0.05 in all 
statistical tests. Statistical analyses were performed 
by SPSS for Windows® 25 (SPSS, Chicago, IL, USA) 
or Prism 7 (GraphPad Inc., La Jolla, CA, USA).
Results
Fluorochrome marker uptake
Calcein labels were readily detectable. They were 
more pronounced in the 2-week healing groups 
than in the 4-week healing groups independent 
of the implant surface (Fig. 2). In addition to the 
incorporation of fluorochrome labels into the 
unaffected secondary spongiosa and endosteum at 
sites of bone formation and mineralisation related to 
normal bone turnover, a large amount of intensive 
calcein labelling was detectable in the peri-implant 
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tissue up to 1 mm distant from the implant surface 
in both groups. Alizarin red, which was applied 
before calcein, was generally rarely visible in the 
peri-implant area at either time point (Fig. 2).
 After 2 weeks of implant insertion and weekly 
sclerostin antibody application, reference implants 
showed calcein labelling adjacent to the implant 
surface, whereas ZOL-coated implants were 
characterised by a more extensive dissemination 
in the peri-implant area (Fig. 2a,c). With increasing 
healing time, a decrease in fluorochrome marker 
uptake was detectable in all experimental groups.
 After 4 weeks and ongoing sclerostin antibody 
application, ZOL-coated implants still revealed 
homogenous bone formation and mineralisation 
surrounding the whole implant. In contrast, in rats 
that received reference surface implants, calcein 
labels were mostly restricted to the cortical bone area, 
whereas there was little label detectable around the 
threads (Fig. 2b,d).
Histomorphology
2 weeks after implant insertion, little peri-implant 
bone was present in rats that received reference 
surface implants only and the implants were mainly 
fixed by cortical bone (Fig. 3a). With ongoing time, 
peri-implant bone loss was more pronounced (Fig. 
3b). In contrast, rats that received reference surface 
implants but combined with sclerostin antibody 
application showed much more cancellous bone in 
the peri-implant area, being mainly located on the 
proximal tibial site of the implants 2 weeks after 
implantation (Fig. 3c). Moreover, distant osteogenesis 
was detectable in this group in line with the systemic 
action of the applied sclerostin antibody. However, 
4 weeks following implant insertion, cancellous bone 
was reduced and the lamellar bone-implant contact 
was predominantly restricted to the tip of the implant 
(Fig. 3d).
 The combination of sclerostin antibody application 
and ZOL implant-coating led to pronounced bone 
formation along the entire implant length. Immature 
woven bone was located within the implant threads 
whereas trabeculae of mature lamellar bone could 
be observed more distantly (Fig. 3g). With increasing 
healing time, bone maturation was observed as 
expected, leading to a homogenous trabecular 
structure and trabeculae in contact with implant 
surfaces (Fig. 3h). When compared with the reference-
surface-coated implants, ZOL-coated implants were 
associated with more woven bone in the peri-implant 
area and the conversion to mature cancellous lamellar 
bone was less pronounced after 4 weeks of healing 
(Fig. 3e-h).
BIC analysed by histomorphometry
Implants with reference surface and antibody 
treatment showed a BIC of 33.2 ± 18.5 % after 2 weeks 
F i g .  2 .  F l u o r e s c e n c e 
microscopy. Multiple image 
alignment: representative 
images of (a ,b)  reference 
implants and (c,d) ZOL-coated 
implants, (a,c) 2 and (b,d) 
4 weeks post-implantation. 
Sclerostin antibody was applied 
in both groups once weekly. 
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of healing, which decreased non-significantly to 
24.1 ± 9.7 % after 4 weeks (Fig. 4a). 2 weeks post-
implantation, the BIC around ZOL-coated implants 
with additional antibody application was comparable 
to that of reference surface implants with combined 
sclerostin antibody therapy (Fig. 4a). In contrast, 
after 4 weeks of healing, the BIC further increased 
significantly to 57.4 ± 15.0 % in rats with ZOL-coated 
implants and sclerostin antibody treatment. This was 
significantly different from the reference groups with 
antibody treatment only. Comparison among groups 
without antibody application revealed a significantly 
increased BIC for ZOL-coated implants after 4 weeks.
BA/TA analysed by histomorphometry
All experimental groups had a higher BA/TA adjacent 
to the implant surface as compared to the distant area 
(Fig. 4b,c). However, relative to reference groups 
and irrespective of antibody treatment, ZOL-coated 
implants showed increased BA/TA adjacent to the 
implant at all time points, reaching significance at 
4 weeks of healing with (32.3 ± 11.5 % for ZOL-coated 
implants versus 10.9 ± 4.4 % for reference-surface-
coated implants) and without combined sclerostin 
antibody treatment (23.8 ± 8.6 % for ZOL-coated 
implants versus 4.5 ± 4.2 % for reference-surface-
coated implants), respectively (Fig. 4b). In the 
Fig. 3. Histology. Masson-
Goldner trichrome staining; 
multiple image alignment: 
representative images of 
(a,b,c,d) reference implants 
and (e,f,g,h) ZOL-coated 
implants, (a ,c,e ,g) 2 and 
(b ,d ,f ,h )  4  weeks post-
implanta t ion .  (c ,d ,g ,h ) 
Sclerostin antibody was 
applied in both groups once 
weekly. 
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distant area, the combination of ZOL coating and 
antibody application led to a significantly increased 
BA/TA at 4 weeks post-implantation as compared 
to reference-coated implants without sclerostin 
antibody treatment (Fig. 4c).
BIC analysed by µCT
Without antibody application or ZOL implant-
coating, BIC decreased non-significantly during 
healing (Fig. 5a). After 4 weeks, the highest BIC was 
detected for ZOL-coated implants with antibody 
treatment (60.0 ± 2.5 %), which was followed by 
ZOL-coated implants without antibody application 
(47.8 ± 10.4 %), albeit the difference between these 
two groups did not reach statistical significance. 
However, the difference between the ZOL-coated 
implant groups and the reference implant groups 
was statistically significant at the 4-week time point 
(Fig. 5a). Overall, these findings were in line with the 
histomorphometry results.
Cancellous bone mass analysed by µCT
The relative cancellous bone volume (BV/TV) 
as well as cancellous BMD were significantly 
increased for ZOL-coated implants at 4 weeks post-
implantation (Fig. 5b,c). 4 weeks post-implantation, 
BV/TV measured for the reference surface group was 
4.7 ± 3.5 %, whereas it was 6 times higher (31.0 ± 7.6 %) 
for the ZOL-coated surface group with sclerostin 
antibody treatment. Likewise, the combination of 
implant coating and antibody administration led to 
an almost 2-fold increase in BMD as compared to 
the reference surface group after 4 weeks of healing 
(Fig. 5c). The comparison of the two experimental 
groups with antibody treatment revealed obvious 
differences regarding the dynamic development 
of cancellous bone mass. Implants with reference 
surface displayed a decrease in BV/TV and BMD 
with proceeding healing time, whereas the coating 
with ZOL promoted bone mass and density increases 
(Fig. 5b,c).
 The analysis of the trabecular thickness revealed 
comparable results for groups which had received 
the sclerostin antibody treatment. Both sclerostin-
antibody-treated groups displayed higher trabecular 
thickness as compared to groups without sclerostin 
antibody treatment (Fig. 5d).
Biomechanical properties
Removal torque as well as stiffness were comparable 
after 2 weeks of healing (Fig. 6). Irrespective of the 
implant surface coating, both parameters increased 
with healing time, but ZOL-coated implants 
displayed a higher removal torque at 4 weeks 
Fig. 4. Histomorphometry parameters 2 and 4 weeks post-implantation. (a) BIC, (b) adjacent and (c) 
distant BA/TA were quantified. Statistical significance is designated as follows: a p < 0.05 versus reference 
coating without sclerostin antibody at same time point; b p < 0.05 versus reference coating with sclerostin 
antibody at same time point; c p < 0.001 versus reference coating without sclerostin antibody at 2 weeks 
post-implantation; d p < 0.05 versus reference coating with sclerostin antibody at 2 weeks post-implantation; 
e p < 0.05 versus ZOL coating without sclerostin antibody at 2 weeks post-implantation; f p < 0.05 versus ZOL 
coating with sclerostin antibody at 2 weeks post-implantation.
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post-implantation when compared with reference 
implants. After 4 weeks, the combination of ZOL-
coating and sclerostin antibody application led to a 
significantly increased removal torque as compared 
to antibody treatment only (Fig. 6a). With exception 
of the statistically increased stiffness of reference-
coated implants at 4 as compared to 2 weeks post-
implantation, no statistically significant differences 
were measurable for implant interface stiffness (Fig. 
6b).
Discussion
The present study evaluated the effect of a 
combination of ZOL implant-coating with systemic 
bone anabolic sclerostin antibody treatment versus 
uncoated reference implants with sclerostin antibody 
treatment or ZOL implant-coating only in a rat 
osteoporosis model. The study hypothesis was that 
the combination of sclerostin antibody application 
and ZOL coating promoted more osseointegration 
than either agent alone. This could be verified by 
histomorphometrical and mechanical testing.
 After 4 weeks of healing, sclerostin antibody 
therapy combined with ZOL implant-coating led 
to a significant increase in BIC, BA/TA adjacent 
to the implant, cancellous BV/TV and BMD as 
well as removal torque as compared to animals 
receiving only sclerostin antibody treatment or 
only ZOL implant-coating. Likewise, the dynamics 
of peri-implant bone deposition differed. Only the 
combination treatment induced sustained peri-
implant bone deposition displayed by rising BIC 
and BA/TA values over time between 2 and 4 weeks 
post-implantation. This significant increase could be 
Fig. 5. µCT parameters 2 and 4 weeks post-implantation. (a) BIC, (b) BV/TV, (c) cancellous BMD and (d) 
trabecular thickness were measured in an area of 200 µm surrounding the implant. Statistical significance 
is designated as follows: a p < 0.05 versus reference coating without sclerostin antibody at same time point; 
b p < 0.01 versus reference coating with sclerostin antibody at same time point; c p < 0.01 versus ZOL coating 
without sclerostin antibody at same time point; d p < 0.05 versus reference coating without sclerostin antibody 
at 2 weeks post-implantation; e p < 0.05 versus reference coating with sclerostin antibody at 2 weeks post-
implantation; f p < 0.001 versus ZOL coating without sclerostin antibody at 2 weeks post-implantation; 
g p < 0.05 versus ZOL coating with sclerostin antibody at 2 weeks post-implantation. 
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explained by a complementary mechanism of action 
of both pharmacologic agents. ZOL primarily has an 
anti-resorptive function due to osteoclast inhibition 
(Im et al., 2004), thus maintaining the peri-implant 
bone. Secondarily, bisphosphonates can also elicit 
an osteoanabolic effect (Im et al., 2004). Conversely, 
sclerostin antibody acts mainly as osteoanabolic, 
by increasing osteoblastic lamellar bone formation 
on existing bone surfaces, but can also exert anti-
resorptive effects (McClung, 2017). Therefore, the 
combination of both agents is expected to result in a 
strong anti-resorptive effect in the peri-implant bone 
area and an osteoanabolic effect in the surrounding 
bone tissue. This can be clinically associated with an 
improved osseointegration of orthopaedic or dental 
implants (Virdi et al., 2012; Virdi et al., 2015).
 The effect of sclerostin antibody application 
on implant osseointegration and bone healing has 
been previously assessed in small animal models. 
Agholme et al. (2010) analysed the pull-out strength 
of metaphyseal inserted steel screws in a rat model 
after 2 and 4 weeks. A similar study was performed 
by Virdi et al. (2012). The insertion of acid-etched 
implants into the medullar canal of murine femora 
combined with sclerostin antibody injection twice 
a week led to an increased mechanical fixation of 
the implants in accordance with Agholme et al. 
(2010). Based on these promising results in non-
compromised bone tissue, subsequent studies used 
animal models simulating systemic bone diseases, 
such as osteoporosis. OVX rats are a standard model 
of postmenopausal osteoporosis (Thompson et al., 
1995). Similarly to the present study, Virdi et al. 
(2015) used this model to quantify the improvement 
of implant fixation caused by sclerostin antibody 
treatment. Titanium implants were inserted into the 
femoral medullar cavity of OVX rats. A sclerostin 
antibody was administered twice per week (25 mg/
kg) for 4, 8 or 12 weeks. When compared to an OVX 
control group, antibody treatment led to enhanced 
BIC, peri-implant trabecular thickness and volume, as 
well as increased cortical thickness. The stimulation 
of bone formation was also detectable in the present 
study, but to a lesser extent. In comparison with 
implants placed into oestrogen-competent rat, the 
antibody could not fully compensate for the effect 
of ovariectomy on bone architecture (Stadlinger et 
al., 2013). One possible explanation could be the 
promotion of lamellar bone formation by antibody 
treatment solely on existing trabeculae (Virdi et al., 
2015). Furthermore, the impact of the healing phase 
has to be considered. The most pronounced effect 
of the sclerostin antibody can be expected during 
the bone remodelling phase following implantation 
(Virdi et al., 2012). In case of OVX rats, a remodelling 
time between 4 and 8 weeks post-implantation is 
reported (Virdi et al., 2012). Therefore, a 2 weeks 
observation period following implantation, as in the 
present study, might be too short to display the whole 
therapeutic potential of the sclerostin antibody.
 B isphosphonates  can  be  adminis tered 
in various ways. In animal studies analysing 
implant osseointegration, systemic administration 
by subcutaneous (Viera-Negron et al., 2008) or 
Fig. 6. Mechanical testing of implant osseointegration 2 and 4 weeks post-implantation. (a) Removal 
torque and (b) stiffness were quantified. Statistical significance is designated as follows: a p < 0.0001 versus 
reference coating without sclerostin antibody at same time point; b p < 0.01 versus reference coating with 
sclerostin antibody at same time point; c p < 0.001 versus ZOL coating without sclerostin antibody at same 
time point; d p < 0.05 versus reference coating without sclerostin antibody at 2 weeks post-implantation; 
e p < 0.0001 versus reference coating with sclerostin antibody at 2 weeks post-implantation; f p < 0.05 versus 
ZOL coating without sclerostin antibody at 2 weeks post-implantation; g p < 0.05 versus ZOL coating with 
sclerostin antibody at 2 weeks post-implantation.
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intravenous (Yildiz et al., 2010) administration routes 
as well as the application as an implant coating 
component (Gao et al., 2009; Langhoff et al., 2008; 
Wermelin and Suska et al., 2008) have been previously 
reported. Studies analysing bisphosphonate 
containing implant coatings have shown a local effect 
of the agent in an area of about 1 mm within the peri-
implant tissue region (Abtahi et al., 2010; Wermelin 
and Suska et al., 2008). Thus, the therapeutic effect 
appears to take place only within the clinically 
relevant peri-implant area and, therefore, may reduce 
or avoid possible systemic side effects. Up to now, 
osteonecrosis of the jaw has not been described to 
occur surrounding bisphosphonate-coated implants 
(Abtahi et al., 2010). Nevertheless, safety aspects 
have to be considered, especially prior to clinical 
studies using bisphosphonate-coated implants. 
Different bisphosphonates such as alendronic acid 
or ZOL show differences in therapeutic potential and 
pharmacologic profile due to their specific chemical 
structure. ZOL probably has the highest potential to 
promote osseointegration in OVX-rats (Andersson 
et al., 2010; Gao et al., 2009). ZOL-coated implant 
surfaces have been previously used in preclinical 
studies in OVX rats (Gao et al., 2009; Stadlinger et 
al., 2013). Gao et al. (2009) measured significantly 
increased BIC and BV/TV values after 12 weeks of 
healing with the bisphosphonate being detectable 
on the implant surface up to 21 d following surgery. 
The same effect on bone formation could be observed 
using a lower ZOL concentration. Interestingly, 
a significant effect on peri-implant bone healing 
is not detectable until the fourth week of healing, 
although surface release kinetics in vitro show a 
release of ZOL within less than 21 d (Stadlinger et 
al., 2013). Therefore, the sustained therapeutic effect 
of bisphosphonate coatings may be explained by the 
local recycling of the pharmaceutical agent. After 
4 weeks of healing, a BIC of 43.2 ± 17.8 % in OVX 
rats receiving ZOL-coated implants was measured 
by histomorphometry. In comparison, the additional 
application of sclerostin antibody in the present 
study lead to a BIC of 57.4 ± 15.0 %, demonstrating 
an increased therapeutic benefit. Moreover, this 
further increase almost reached the level of the non-
OVX reference group as reported by Stadlinger et al. 
(2013). Cancellous BV/TV adjacent and distant to the 
implant were similarly increased, emphasising the 
pharmacological potential of a combined application 
of sclerostin antibody and ZOL coating on peri-
implant bone formation. The concept of an add-on 
therapy to increase bone mass in osteoporotic bone 
and, thus, to improve implant osseointegration has 
already been described by Li et al. (2011). In OVX rats 
with established osteopaenia, the bisphosphonate 
alendronic acid and/or sclerostin antibody were 
systemically applied. After 12 weeks, increased 
trabecular bone volume and bone strength were 
measured in all antibody-treated groups irrespective 
of the systemic alendronic acid application (Li et 
al., 2011). Halleux et al. (2009) analysed the effect of 
ZOL and sclerostin antibody combination therapy 
on bone mass in OVX mice treated immediately after 
ovariectomy. In this setting of active bone loss, loss 
was prevented and bone mass was increased to a 
greater extent when using the combination therapy 
as compared to either agent alone.
Limitations of the study
In the field of dental implant research, small and large 
animal models are well-established (Berglundh et 
al., 2012). Histological analyses, which are necessary 
to evaluate new implant modifications, are easier to 
perform in preclinical models than in clinical settings. 
Stadlinger et al. (2012b) reviewed the animal models 
applied in 271 preclinical dental implant studies. 
Almost half of the studies were performed in small 
animal models (123 studies; 45.4 %). Especially, for 
the first reported in vivo study of a new dental implant 
or implant modification, small animals are the model 
of choice. Rats and rabbits are the most commonly 
used small animals in dental implantology (Dereka 
et al., 2018; Stadlinger et al., 2012b). In rats, symptoms 
of postmenopausal osteoporosis can be induced 
by ovariectomy with well-known phenotypic 
consequences of strongly enhanced osteoclastic bone 
resorption (Kimmel, 2002; Komori 2015).
 The distribution of implant sites was also analysed 
by Stadlinger et al. (2012b). Irrespective of the selected 
animal model, mainly extraoral implant sites are 
used (61 %) for which the tibia is the most common 
location. In small animals, such as rats, the application 
of implants with an adequate size is much easier 
using extraoral sites, because no tooth extraction is 
required before implant insertion and often there is 
more space for surgical intervention. In addition, 
small animals cannot be trained for oral hygiene 
and intraoral wound protection after surgery, which 
might influence implant healing. The disadvantage 
of extraoral versus intraoral implant insertion is the 
missing interaction of the oral microbiome as well 
as the mechanical strain from the chewing forces on 
the osseointegration process. Nevertheless, the tibia 
is also mechanically loaded by the natural movement 
of the rat and is amenable to controlled loading, 
allowing the study of the effects of mechanical load 
on implant healing (Duyck and Vandamme, 2014).
 The different embryological origin of craniofacial 
and long bones, such as the tibia, need to be 
addressed. Neural crest cells represent a multipotent 
cell population which undergo an epithelial-
mesenchymal transition during migration from 
the neural tube, building the jaw bones through 
intramembranous ossification (Noce et al., 2014). In 
contrast, long bones are of paraxial mesodermal origin 
and develop through endochondral ossification. The 
scientific community is still debating if the source 
of stem cells for mineralised tissue regeneration in 
the craniomaxillofacial region might influence the 
repairing result (d`Aquino et al., 2011). Alge et al. 
(2010) concluded that dental pulp stem cells are 
more suitable for craniomaxillofacial repair than 
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bone marrow stem cells because of the differing 
embryological origin. Therefore, it is possible that 
the chosen implant site also has an impact, in terms 
of differing embryological origin, on the osseous 
healing after implant insertion. Nevertheless, when 
comparing the overall structure of jaw and tibial 
bone, dense cortical bone surrounds a cancellous 
bone compartment, suggesting overall comparable 
implant sites. The focus of the present study was the 
evaluation of implant healing and osseointegration 
within the first 4 weeks of bone healing. Future 
studies will need to evaluate the long-term effects 
of bisphosphonate coating and sclerostin antibody 
administration.
 Yu et al.  (2018) used a non-osteoporotic 
experimental alveolar ridge tooth extraction rat 
model and administered the antibody starting on 
the day of surgery. Sclerostin-antibody-treated 
and control groups were sacrificed after 10, 14 and 
28 d and their maxillae were evaluated by µCT, 
histology and histomorphometry. Results indicated 
that systemic sclerostin antibody administration 
enhanced osseointegration and bone regeneration 
around dental implants also at compromised alveolar 
bone osteotomy sites. It was concluded that the 
approach offers potential as a treatment modality 
for patients with low bone mass or bone defects to 
achieve a more predictable bone regeneration at 
alveolar bone defects and to enhance dental implant 
osseointegration. This is in line with the present 
study results. In addition, findings demonstrated 
that, in an osteoporosis model, the beneficial effect 
of osteoanabolic sclerostin antibody therapy can be 
further increased by using a ZOL implant-coating.
 The present preclinical study showed promising 
results in a rat model of postmenopausal osteoporosis 
regarding the stimulation of implant osseointegration 
in a compromised bone setting. While promising, 
these results should still be validated in a larger 
animal model, e.g. the osteoporotic minipig, in 
which dental implants can be inserted intraorally 
(Stadlinger et al., 2012b). Currently, ZOL, like all 
other bisphosphonates, is clinically approved but 
not licensed as a dental implant coating. Recently, 
the anti-sclerostin antibody romosozumab has 
been approved by the Japanese Pharmaceuticals 
and Medical Devices Agency and is under review 
with the European Medicines Agency and the US 
Food and Drug Administration for the treatment 
of osteoporotic patients at high fracture risk. The 
question whether systemic sclerostin antibody 
therapy is also justifiable merely to increase implant 
osseointegration needs to be carefully addressed. 
Consensus is that the oral reconstruction after tooth 
loss is necessary to restore masticatory, speech 
and aesthetic functions of the patient. The dental 
reconstruction can be performed by removable and 
non-removable dental prostheses. Especially in 
cases of complete tooth loss, the stable fixation of 
the prosthesis is limited due to the anatomy of the 
edentulous jaw. The patients benefit greatly from 
fixation of the prosthesis by dental implants, because 
the ability to eat normally is not just important from 
the medical point of view, but it also increases the 
patients’ overall well-being and satisfaction. Because 
of the demographic development in the industrial 
nations, the number of aging and diseased patients 
with compromised osteoporotic bone requiring 
treatment is expected to increase rapidly in the 
future. For these patients with compromised bone, 
systemic osteoanabolic principles, such as sclerostin 
antibody therapy in combination with implant 
coatings, might be one way to benefit from the 
advantages of a fixed denture. Nevertheless, careful 
consideration of the risks and possible benefits for 
the patient remains to be always undertaken. It is 
also conceivable that a sustained-release formulation 
of sclerostin antibody can be developed for local 
use in patients with compromised bone in order to 
enhance dental implant osseointegration. To ensure 
the long-term success of such a local application 
strategy, more preclinical dose-regimen studies are 
needed to better understand during which phase of 
implant wound healing and osseointegration the 
osteoanabolic properties of the anti-sclerostin therapy 
are contributing most. Likely, local application of 
sclerostin antibody would require sustained drug 
release over time, which might be achieved by 
sclerostin antibody implant coating. From a technical 
point of view, this may be challenging, especially 
if two different components such as a sclerostin 
antibody and ZOL shall be combined.
 Dental implants enable functional and aesthetic 
rehabilitation after tooth loss. However, compromised 
host bone can be a limitation for implant placement 
and the clinical long-term success may be reduced. 
Therefore, it is of interest to promote peri-implant 
bone formation using implant coatings and to restore 
adjacent cancellous bone mass and structure with a 
systemic bone anabolic agent in patients at risk. In the 
current study, the combination of anti-resorptive ZOL 
implant coating and systemically applied sclerostin 
antibody led to significantly increased BIC, BV/TV, 
BA/TA, BMD and removal torque in an osteoporotic 
rat model after 4 weeks of healing as compared 
to rats only receiving reference coated implants 
and sclerostin antibody treatment. Therefore, the 
combination of ZOL and osteoanabolic sclerostin 
antibody has the potential to be more effective than 
either agent alone.
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Discussion with Reviewer
Babak Chehroudi: Implant coatings are often 
unstable in post-surgical environments where 
abundance of proteolytic enzyme and inflammatory 
cells can destabilise them rapidly. Did some of the 
long-term results of this experiment suggest that the 
implant coating was removed? How long materials 
such as ZOL remain on the implant surface in the 
harsh post-trauma environment?
Authors: Stadlinger et al. (2013) showed an in vitro 
ZOL-coating release of 71.1 ± 4.7 % after 14 d. This 
is in accordance with the findings of Gao et al. 
(2009), who showed a release of bisphosphonates 
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from the implant surface over a period of 21 d. 
Clinically, bisphosphonates such as ZOL are taken 
up by osteoclasts and, after apoptosis of the cell, the 
drug is released again into the extracellular matrix. 
Subsequently, the bisphosphonate can again be 
absorbed by osteoclasts (Li, 1996). The local recycling 
of ZOL leads to a very long half-life of this class of 
drugs, differently from protein implant coatings 
with e.g. extracellular matrix components. Therefore, 
the long-term effectiveness of bisphosphonates as 
implant coatings might not only be determined by 
the initial drug release kinetics.
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